Concepedia

Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus

Carol Addy, Daniel Tatosian, Xiaoli S. Glasgow, Isaias Noel Gendrano, Eunkyung Kauh, Ashley Martucci, Amy O. Johnson‐Levonas, Diana Selverian, Catherine Z. Matthews, Marie Gutierrez,

Clinical Therapeutics · 2016 · 27 citations · 14 references

DOI

Concepts

References

14

Dipeptidyl‐peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon‐like peptide‐1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum

Rolf Mentlein, Baptist Gallwitz, Wolfgang E. Schmidt · European Journal of Biochemistry · 1993 · 1.2K citations · Full text

, , +17

Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes

Pablo Aschner, Mark Kipnes, Jared Lunceford et al. · Diabetes Care · 2006 · 881 citations

, , +17

Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial

Michael A. Nauck, Gary Meininger, Lisa Terranella et al. · Diabetes Obesity and Metabolism · 2007 · 667 citations · Full text

, , +17

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus

Itamar Raz, M Hanefeld, Lei Xu et al. · Diabetologia · 2006 · 617 citations · Full text

, , +13

Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits

Daniel J. Drucker, Steven I. Sherman, Fred S. Gorelick et al. · Diabetes Care · 2010 · 309 citations · Full text

, , +13